Everything we do is to move us closer to our goal, of finding new treatments to slow, stop or reverse the progression of Parkinson’s. Our leadership and funding enables the world’s leading neuroscientists and neurologists to prioritise, together, the next generation of drugs for clinical trial. We’re acting with urgency, for people currently living with Parkinson’s, with a focus on research which has potential to translate into the clinic within five years.
